Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
Conditions: Primary Immune Deficiency Disorder; Immune Deficiency Disease; Bone Marrow Failure Interventions: Drug: Alemtuzumab; Drug: Fludarabine; Drug: Melphalan; Radiation: Low Dose Total Body Irradiation; Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate Mofetil Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Marrow Failure Syndrome (BMFS) | Cancer | Cancer & Oncology | Prograf | Research | Tacrolimus | Transplants